Literature DB >> 27278272

Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies.

Yanli Li1, Zandra Klippel2, Xiaolong Shih3, Maureen Reiner4, Hong Wang5, John H Page6.   

Abstract

PURPOSE: Chemotherapy-induced neutropenia (CIN) may increase infection risk for cancer patients; however, there is limited understanding on the quantitative relationships between severity and duration of CIN and infection risk.
METHODS: This study combined individual data from adult cancer patients receiving no granulocyte colony-stimulating factor during the first chemotherapy cycle in six trials. We used area over the curve (AOC) of absolute neutrophil count (ANC) time-response curve (below different thresholds) to measure the combined effect of severity and duration of CIN. Time-dependent Cox proportional hazards models quantified the hazard of first infection associated with duration of grade 4 or grade 3/4 CIN and the hazard associated with AOC.
RESULTS: We analyzed data from 271 patients who had small cell lung cancer, non-Hodgkin's lymphoma, head and neck cancer, or breast cancer; 63.8 % of the patients had advanced cancer, and 77.5 % received chemotherapy regimens with high risk of febrile neutropenia. In the first cycle, 18.8 % of the patients had infection-related hospitalizations. Each additional day patients had grade 3/4 or grade 4 CIN was associated with 28 % (95 % CI 7, 51 %) and 30 % (95 % CI 10, 54 %) increased risk of infection-related hospitalization, respectively. Each unit increase in AOC (day × 10(9)/L ANC), with threshold of ANC < 0.5 × 10(9)/L, was associated with a significantly increased risk of infection-related hospitalization (hazard ratio 1.98; 95 % CI 1.35, 2.90).
CONCLUSIONS: Infection risk increases dramatically with each additional day of grade 3 or 4 CIN. Interventions limiting CIN severity and duration are of critical importance to reduce infection risk in cancer patients receiving chemotherapy.

Entities:  

Keywords:  Area over the curve; Chemotherapy-induced neutropenia; Infection; Infection-related hospitalization

Mesh:

Year:  2016        PMID: 27278272     DOI: 10.1007/s00520-016-3277-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  35 in total

1.  Simplified calculation of body-surface area.

Authors:  R D Mosteller
Journal:  N Engl J Med       Date:  1987-10-22       Impact factor: 91.245

2.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Leon E Cosler; Gary H Lyman
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

3.  Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.

Authors:  Michelle Shayne; Jeffrey Crawford; David C Dale; Eva Culakova; Gary H Lyman
Journal:  Breast Cancer Res Treat       Date:  2006-05-17       Impact factor: 4.872

4.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.

Authors:  G Bonadonna; P Valagussa; A Moliterni; M Zambetti; C Brambilla
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

5.  Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

Authors:  Gary H Lyman; David C Dale; Jonathan Friedberg; Jeffrey Crawford; Richard I Fisher
Journal:  J Clin Oncol       Date:  2004-09-20       Impact factor: 44.544

6.  Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study.

Authors:  Ruth Pettengell; Matthias Schwenkglenks; Robert Leonard; André Bosly; Robert Paridaens; Manuel Constenla; Thomas D Szucs; Christian Jackisch
Journal:  Support Care Cancer       Date:  2008-03-20       Impact factor: 3.603

7.  Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

Authors:  V Trillet-Lenoir; J Green; C Manegold; J Von Pawel; U Gatzemeier; B Lebeau; A Depierre; P Johnson; G Decoster; D Tomita
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

8.  History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis.

Authors:  C Chao; J H Page; S-J Yang; R Rodriguez; J Huynh; V M Chia
Journal:  Ann Oncol       Date:  2014-06-10       Impact factor: 32.976

9.  Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.

Authors:  Jeffrey Crawford; David C Dale; Nicole M Kuderer; Eva Culakova; Marek S Poniewierski; Debra Wolff; Gary H Lyman
Journal:  J Natl Compr Canc Netw       Date:  2008-02       Impact factor: 11.908

10.  First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study.

Authors:  Edgardo Rivera; M Haim Erder; Moshe Fridman; Debra Frye; Gabriel N Hortobagyi
Journal:  Breast Cancer Res       Date:  2003-06-20       Impact factor: 6.466

View more
  12 in total

1.  A retrospective study on prephase therapy prior to definitive multiagent chemotherapy in aggressive lymphomas.

Authors:  Luis Malpica; Bolanle Mufuka; Jonathan Galeotti; Xianming Tan; Natalie Grover; Stephen M Clark; Anne Beaven; Hyman Muss; Christopher Dittus
Journal:  Leuk Lymphoma       Date:  2020-02-09

2.  Revisiting Infectious Complications Following Total Parenteral Nutrition Use During Hematopoietic Stem Cell Transplantation.

Authors:  Halina Rubin; Jayesh Mehta; Jessica L Fong; Deborah Greenberg; Solomiya GrusChak; Steven Trifilio
Journal:  J Adv Pract Oncol       Date:  2020-09-01

3.  Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.

Authors:  Davey Daniel; Vladimer Kuchava; Igor Bondarenko; Oleksandr Ivashchuk; Sreekanth Reddy; Jana Jaal; Iveta Kudaba; Lowell Hart; Amiran Matitashvili; Yili Pritchett; Shannon R Morris; Jessica A Sorrentino; Joyce M Antal; Jerome Goldschmidt
Journal:  Int J Cancer       Date:  2020-12-21       Impact factor: 7.396

Review 4.  International consensus on severe lung cancer-the first edition.

Authors:  Chengzhi Zhou; Shiyue Li; Jun Liu; Qian Chu; Liyun Miao; Linbo Cai; Xiuyu Cai; Yu Chen; Fei Cui; Yuchao Dong; Wen Dong; Wenfeng Fang; Yong He; Weifeng Li; Min Li; Wenhua Liang; Gen Lin; Jie Lin; Xinqing Lin; Hongbing Liu; Ming Liu; Xinlin Mu; Yi Hu; Jie Hu; Yang Jin; Ziming Li; Yinyin Qin; Shengxiang Ren; Gengyun Sun; Yihong Shen; Chunxia Su; Kejing Tang; Lin Wu; Mengzhao Wang; Huijuan Wang; Kai Wang; Yuehong Wang; Ping Wang; Hongmei Wang; Qi Wang; Zhijie Wang; Xiaohong Xie; Zhanhong Xie; Xin Xu; Fei Xu; Meng Yang; Boyan Yang; Xiangjun Yi; Xiaoqun Ye; Feng Ye; Zongyang Yu; Dongsheng Yue; Bicheng Zhang; Jian Zhang; Jianqing Zhang; Xiaoju Zhang; Wei Zhang; Wei Zhao; Bo Zhu; Zhengfei Zhu; Wenzhao Zhong; Chunxue Bai; Liangan Chen; Baohui Han; Chengping Hu; Shun Lu; Weimin Li; Yong Song; Jie Wang; Caicun Zhou; Jianying Zhou; Yanbin Zhou; Yuichi Saito; Yoshinobu Ichiki; Hitoshi Igai; Satoshi Watanabe; Sara Bravaccini; Alfonso Fiorelli; Francesco Petrella; Takeo Nakada; Piergiorgio Solli; Nikolaos Tsoukalas; Yuki Kataoka; Taichiro Goto; Rossana Berardi; Jianxing He; Nanshan Zhong
Journal:  Transl Lung Cancer Res       Date:  2021-06

Review 5.  Divergent Sepsis Pathophysiology in Older Adults.

Authors:  Meagan S Kingren; Marlene E Starr; Hiroshi Saito
Journal:  Antioxid Redox Signal       Date:  2021-10-01       Impact factor: 8.401

6.  CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.

Authors:  Kai Rejeski; Ariel Perez; Pierre Sesques; Eva Hoster; Carolina Berger; Liv Jentzsch; Dimitrios Mougiakakos; Lisa Frölich; Josephine Ackermann; Veit Bücklein; Viktoria Blumenberg; Christian Schmidt; Laurent Jallades; Boris Fehse; Christoph Faul; Philipp Karschnia; Oliver Weigert; Martin Dreyling; Frederick L Locke; Michael von Bergwelt-Baildon; Andreas Mackensen; Wolfgang Bethge; Francis Ayuk; Emmanuel Bachy; Gilles Salles; Michael D Jain; Marion Subklewe
Journal:  Blood       Date:  2021-12-16       Impact factor: 22.113

7.  Early antimicrobial prophylaxis in autologous stem cell transplant recipients: Conventional versus an absolute neutrophil count-driven approach.

Authors:  Justin G Horowitz; Gerard W Gawrys; Grace C Lee; Brittney A Ramirez; Carole M Elledge; Paul J Shaughnessy
Journal:  Transpl Infect Dis       Date:  2021-07-30

8.  Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.

Authors:  Sibylle Schirm; Christoph Engel; Sibylle Loibl; Markus Loeffler; Markus Scholz
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-04       Impact factor: 4.553

9.  Validation of Risk of Chemotherapy-Induced Neutropenia: Experience from Oncology Hospital of Nepal.

Authors:  Ronash Shrestha; Safin Chapagai; Dip Kiran Shakya; Prashant Bista; Binaya Sapkota
Journal:  Cancer Manag Res       Date:  2020-05-20       Impact factor: 3.989

10.  Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study.

Authors:  Claas-Frederik Johannsen; Tonny Studsgaard Petersen; Jimmi Nielsen; Anders Jørgensen; Espen Jimenez-Solem; Anders Fink-Jensen
Journal:  Ther Adv Psychopharmacol       Date:  2022-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.